Efficacy and Safety of Combination Androgen‐Receptor Signaling Inhibitors, Denosumab, and Local Radiotherapy for Poly‐Metastatic Prostate Cancer
Cancer Reports · 2025
DOI: 10.1002/cnr2.70355 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Makoto Kawase und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan. Hauptthemen laut MEDLINE: Denosumab, Bone Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Androgen Receptor Antagonists. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma Inc., Astellas Pharma.
Abstract (Originalsprache)
Background
The Treatment of Metastatic Castration‐Sensitive Prostate Cancer ( mCSPC ) has dramatically changed over the past decade. To improve oncological outcomes, pharmacological treatments have evolved to include two‐or three‐drug combinations, and the efficacy of local radiation therapy ( LRT ) at the prostate combined with denosumab chemotherapy has been discussed.
Aims
This study aimed to provide an interim evaluation of the combination of androgen receptor signaling inhibitors denosumab, LRT , and metastasis‐directed therapy ( MDT ) for prostate cancer with multiple bone metastases (poly‐ PCa ).
Methods
We are currently conducting a single‐arm prospective study to evaluate the combination of enzalutamide, LRT , denosumab, and MDT in terms of improving oncological outcomes in patients with poly‐ PCa . The primary endpoints were prostate‐specific antigen ( PSA )‐based progression‐free survival ( PFS ) and radiographic PFS ( rPFS ).
Results
Twenty patients have been enrolled in the study to date. The median follow‐up period thus far is 18.0 months (interquartile range, 14.0–25.8 months). The 1‐year PFS rate is 84.4% at present, and the rPFS rate is 100%. Seventeen patients (85.0%) achieved a PSA reduction of ≥ 90% versus their baseline values at enrollment, and 10 (50.0%) maintained PSA levels of < 0.2 ng/ mL .
Conclusion
This treatment strategy is expected to improve the oncological outcomes of patients with poly‐ PCa . A more comprehensive report of this study with more patients and a longer observation period is forthcoming.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.
ORCID-Profile: Makoto Kawase, Kota Kawase, Yuki Tobisawa, Koji Iinuma, Keita Nakane, Takuya Koie
Förderung
- Astellas Pharma Inc.
- Astellas Pharma
Zitieren
APA
Kawase, M., Kawase, K., Tobisawa, Y., Iinuma, K., Nakane, K., & Koie, T. (2025). Efficacy and Safety of Combination Androgen‐Receptor Signaling Inhibitors, Denosumab, and Local Radiotherapy for Poly‐Metastatic Prostate Cancer. Cancer Reports. https://doi.org/10.1002/cnr2.70355
Vancouver
Kawase M, Kawase K, Tobisawa Y, Iinuma K, Nakane K, Koie T. Efficacy and Safety of Combination Androgen‐Receptor Signaling Inhibitors, Denosumab, and Local Radiotherapy for Poly‐Metastatic Prostate Cancer. Cancer Reports. 2025. doi:10.1002/cnr2.70355
BibTeX
@article{Kawase2025,
author = {Kawase, Makoto and Kawase, Kota and Tobisawa, Yuki and Iinuma, Koji and Nakane, Keita and Koie, Takuya},
title = {Efficacy and Safety of Combination Androgen‐Receptor Signaling Inhibitors, Denosumab, and Local Radiotherapy for Poly‐Metastatic Prostate Cancer},
journal = {Cancer Reports},
year = {2025},
doi = {10.1002/cnr2.70355}
}
EUVIMED